Cross-platform analytical assessment of serum GFAP quantification in multiple sclerosis: SIMOA versus two automated immunoassays
Automated platforms, particularly Lumipulse, showed strong concordance with SIMOA supporting the role in analytical monitoring.
Authors
- Raquel Gasqué-Rubio (ORCID: https://orcid.org/0000-0001-6262-7499)
- Sara Carratalà‐Boscà (ORCID: https://orcid.org/0000-0003-0021-3041)
- Laura Cubas-Núñez (ORCID: https://orcid.org/0000-0003-4934-3891)
- Francisco Pérez‐Miralles (ORCID: https://orcid.org/0000-0003-3767-3738)
- Jordi Tortosa-Carreres (ORCID: https://orcid.org/0000-0002-4622-2173)
- Begoña Laiz-Marro (ORCID: https://orcid.org/0009-0003-1526-3575)
- Carmen Alcalà-Vicente
- Jéssica Castillo-Villalba (ORCID: https://orcid.org/0009-0005-4578-8406)
- Lorena Forés-Toribio
- Carlos Quintanilla-Bordas
- Bonaventura Casanova
- Ana Vañó-Bellver (ORCID: https://orcid.org/0000-0002-5103-6447)
Institutions
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital de La Ribera (ES)
- Hospital General Universitari de Castelló (ES)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-20
- DOI
- https://doi.org/10.3389/fneur.2025.1682198
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00